The GTF2H5 knockout A-549 polyclonal cell product comprises a CRISPR/Cas9-edited polyclonal knockout population of A-549 human lung carcinoma cells, in which the GTF2H5 gene has been disrupted to create a loss-of-function model. This heterogeneous pool of edited cells provides a versatile tool for investigating gene function without the clonal selection artifacts that may arise in single-cell-derived lines. The polyclonal format captures the spectrum of genetic variation inherent to CRISPR/Cas9-mediated gene disruption, enabling robust functional studies in a more physiologically relevant context compared to monoclonal lines. As GTF2H5 encodes a vital structural subunit of the TFIIH complex, its knockout abrogates critical cellular processes, making this model suitable for applications in DNA repair, transcription, and cancer biology.
Derived from the lung carcinoma of a 58-year-old Caucasian male, the A-549 cell line exhibits an adherent epithelial morphology and serves as a widely accepted model for alveolar type II pulmonary epithelium. Extensively utilized in cancer and respiratory disease research, A-549 cells retain features relevant to lung adenocarcinoma and are a standard host for studying epithelial biology, drug responses, and oncogenic mechanisms. Their reproducible growth characteristics and genetic background provide a reliable platform for introducing targeted gene disruptions.
GTF2H5 is a core subunit of the general transcription and repair factor TFIIH, where it acts as a stabilizing scaffold for the entire complex. It interacts directly with the helicases XPB and XPD, as well as with other structural subunits such as p62 (GTF2H1), p52 (GTF2H4), p44 (GTF2H2), and p34 (GTF2H3), to maintain complex integrity. This interaction is essential for the helicase activities of XPB and XPD, which are required for promoter melting during transcription initiation by RNA polymerase II and for local DNA unwinding around lesions during nucleotide excision repair (NER). Upstream, TFIIH is activated by DNA-damaging agents including UV radiation, and is recruited to lesions through association with XPC and XPA. Downstream, TFIIH phosphorylates the C-terminal domain (CTD) of RNA polymerase II to promote transcription elongation and drives DNA repair synthesis. The pathway involves collaborative action of TFIIH with Mediator, TBP, TFIIB, RPA, and the ERCC1-XPF endonuclease.
In the A-549 lung carcinoma context, disruption of GTF2H5 compromises both transcription and NER, thereby sensitizing cells to genotoxic agents such as UV radiation and platinum-based chemotherapeutics. This polyclonal knockout model recapitulates molecular features of trichothiodystrophy, a photosensitive developmental disorder linked to TFIIH dysfunction, and provides a platform for studying DNA repair deficiencies in a lung epithelial environment. The interplay between impaired transcription and compromised genome maintenance can be dissected to understand how lung cancer cells may evolve drug resistance or reliance on alternative repair pathways. Furthermore, the A-549 background allows investigation of how the alveolar epithelial phenotype influences the response to GTF2H5 loss, offering insights relevant to pulmonary toxicology and lung carcinogenesis.
Researchers can deploy this model for transcriptome-wide analyses via RNA-seq, chromatin immunoprecipitation (ChIP)-qPCR to assess TFIIH promoter occupancy, and quantitative RT-qPCR to measure transcriptional changes in target genes. Functional studies may involve nucleotide excision repair assays such as unscheduled DNA synthesis (UDS) to gauge repair capacity, immunofluorescence for ??H2AX foci formation after UV irradiation to monitor DNA damage response, and clonogenic survival assays to evaluate cellular sensitivity to genotoxic stress. Additional applications include transcription reporter assays and cell viability screens for drug sensitivity profiling. This GTF2H5 knockout polyclonal cell product serves as a powerful tool for advancing our understanding of the molecular mechanisms linking transcription, DNA repair, and lung cancer biology. For further details or to explore how this model can accelerate your specific research programs, please contact Ascent Research.
